<sup>99</sup>Tc<sup>m</sup>-MIBI显像对肿瘤多药耐药检测的应用

钱习军

⁹⁹Tc^m-MIBI显像对肿瘤多药耐药检测的应用

钱习军

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 4: (173-176)

引用本文:

Citation:

⁹⁹Tc^m-MIBI显像对肿瘤多药耐药检测的应用

钱习军

210009 南京, 东南大学医学院血液肿瘤科

作者简介: 钱习军(1972-),女,安徽无为人,硕士研究生,主要从事肿瘤多药耐药机制及逆转的研究。;

中图分类号: R817.4

The application of ⁹⁹Tc^m-MIBI imaging to detect multidrug resistance

QIAN Xi-jun

Medical College of Southeast University, Jiangsu Nanjing 210009, China
CLC number: R817.4

摘要: MDR(多药耐药)是目前肿瘤化疗失败的主要原因,对MDR的检测可以帮助化疗决策的制定,从而使肿瘤患者得到更有效的治疗。⁹⁹Tc^m-MIBI(⁹⁹Tc^m-甲氧基异丁基异腈)是mdr1基因编码的P-gp(P-糖蛋白)和MRP(多药耐药相关蛋白)的转运底物,肿瘤细胞内⁹⁹Tc^m-MIBI摄取减低表明其P-gp的高表达,并与MRP的表达相关。因此,⁹⁹Tc^m-MIBI显像可在治疗前预测对化疗的反应,并为选择更有效的化疗策略提供依据。
- 多药耐药 /
- ⁹⁹Tc^m-甲氧基异丁基异腈 /
- P-糖蛋白 /
- 多药耐药相关蛋白 /
- 肿瘤
Abstract: Multidrug resistance is the main cause of chemotherapy failure,To detect multidrug resistance is helpful to develop chemotherapy regimens and more effective treatment of patients with tumors. ⁹⁹Tc^m-sestamibi is a transport sub-strate of mdr1-encoded P-glycoprotein and MRP.The lower ⁹⁹Tc^m-sestamibi accumulation indicates the higher expression of P-glycoprotein in tumor cells.It is also related to the expression of MRP.As a result,response to chemotherapy can be estimated before starting treatment by means of ⁹⁹Tc^m-sestamibi imaging and more effective protocol can be chosen.
- multidrug resistance /
- ⁹⁹Tc^m-sestamibi /
- P-glycoprotein /
- multidrug resistance related protein /
- tumor
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Shung-Shung S, Tih-Fang H, Shih-chuan T, et al. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results[J]. Cancer Lett, 2000, 153(1-2):95-100.
[2]	Del-Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J]. J Nucl Med, 1997, 38(9):1348-1351.
[3]	Del-Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistance (MDB1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients[J]. Eur J Nucl Med, 1997, 24(2):150-159.
[4]	Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer[J]. J Nucl Med, 1998, 39(2):228-234.
[5]	Andrews DW, Dss R, Kim S, et al. Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance[J]. Neurosurgery, 1997, 40(6):1323-1332.
[6]	Kapucu LÖ, Akyüz C, Varal G, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi[J]. J Nucl Med, 1997, 38(2):243-247.
[7]	Gruber A, Areström I, Xu D, et al. Multidrug resistance phenotype in leukaemia cells from patients with acute myelocytie leukaemia can be detected with ⁹⁹Tc^m-MIBI[J]. Br J Cancer, 1998, 77(11):1732-1736.
[8]	Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy[J]. J Nucl Med, 1998, 39(7):1191-1197.
[9]	Leitha T, Glaser C, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, P53 expression, or cell proliferation?[J]. Nucl Med Biol, 1998, 25(6):539-541.
[10]	Fujii H, Nakamura K, Kubo A, et al. Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase ⁹⁹Tc^m-MIBI scintimammography[J]. Ann Nacl Med, 1998, 12(6):307-312.
[11]	Kostakoglu L, Ruacan S, Ergün EL, et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer[J]. J Nucl Med, 1998, 39(6):1021-1026.
[12]	Duran-Cordobes M, Moretti JL, De-Beco V, et al. Uptake of liposome-encapsulated ⁹⁹Tc^m-MIBI by sensitive and multidrug-resistant tumour cell lines[J]. Nucl Med Commun, 1999, 20(5):433-437.
[13]	Hendrikse NH, Franssen EJF, Van-der-Graaf WTA, et al.⁹⁹Tc^m-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein[J]. Br J Cancer, 1998, 77(3):353-358.
[14]	Moretti JL, Duran-Cordobes M, Starzec A, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells[J]. J Nucl Med, 1998, 39(7):1214-1218.
[15]	Chia-Hung K, Shih-Chuan T, Tse-Jia L, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings[J]. Cancer Res, 2001, 61(4):1412-1414.
[16]	Chia-Hung K, Shih-Chuan T, Thi-Joung W, et al. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression multidrug resistance-related protein expression and other prognosis factors[J]. Br J Haematol, 2001, 113(2):369-374.
[17]	Zhou J, Higashi K, Ueda Y, et al. Expression of multidrug resistance protein and messenger RNA correlate with ⁹⁹Tc^m-MIBI imaging in patients with lung cancer[J]. J Nucl Med, 2001, 42(10):1476-1483.
[18]	Kabasakal L, Özker K, Hayward M, et al. Technetium-99m sestamibi uptake in human breast carinoma cell lines displaying glutathione-associated drug-resis tance[J]. Eur J Nucl Med, 1996, 23(5):568-570.

[1]	白景明 , 李亚明 . 体内多药耐药的显像研究. 国际放射医学核医学杂志, 1999, 23(5): 208-212.
[2]	黄建敏 , 曲雁 , 潘莉萍 . 恶性骨肿瘤多药耐药的⁹⁹Tc^m-MIBI体层显像研究. 国际放射医学核医学杂志, 2005, 29(4): 169-170.
[3]	程兵 . ⁹⁹Tc^m-MIBI显像检测乳腺癌多药耐药. 国际放射医学核医学杂志, 2002, 26(2): 67-71.
[4]	赵韬 . ⁹⁹Tc^m-MIBI显像检测乳腺癌P-糖蛋白. 国际放射医学核医学杂志, 2004, 28(6): 262-264.
[5]	袁超 , 李卫鹏 . ⁹⁹Tc^m-tetrofosmin:一种评价体内P-糖蛋白功能变化的显像剂. 国际放射医学核医学杂志, 2009, 33(3): 144-148. doi: 10.3760/cma.j.issn.1673-4114.2009.03.005
[6]	张一秋 , 石洪成 . ⁹⁹Tc^m-甲氧基异丁基异腈SPECT预测肺癌多药耐药及化疗疗效. 国际放射医学核医学杂志, 2008, 32(6): 329-332.
[7]	贾志云 , 邓候富 . ⁹⁹Tc^m-甲氧基异丁基异腈显像在白血病中的应用价值. 国际放射医学核医学杂志, 2005, 29(6): 252-254.
[8]	何燕 , 苏晋 , 郑晓霞 , 温莉 , 孙树兰 . P-糖蛋白抑制剂在PET显像中的应用研究. 国际放射医学核医学杂志, 2016, 40(1): 1-5, 21. doi: 10.3760/cma.j.issn.1673-4114.2016.01.001
[9]	白旭东 , 唐志刚 , 王学斌 . ⁹⁹Tc^m标记异腈类配合物的研究进展. 国际放射医学核医学杂志, 2005, 29(1): 19-22.
[10]	刘志军 . ⁹⁹Tc^m-MIBI显像在头颈部恶性肿瘤中的应用. 国际放射医学核医学杂志, 2004, 28(5): 203-206.

点击查看大图

计量

文章访问数: 1010
HTML全文浏览量: 80
PDF下载量: 5

⁹⁹Tc^m-MIBI显像对肿瘤多药耐药检测的应用

钱习军

作者简介:钱习军(1972-),女,安徽无为人,硕士研究生,主要从事肿瘤多药耐药机制及逆转的研究。

210009 南京, 东南大学医学院血液肿瘤科

收稿日期: 2002-04-24

关键词:

摘要: MDR(多药耐药)是目前肿瘤化疗失败的主要原因,对MDR的检测可以帮助化疗决策的制定,从而使肿瘤患者得到更有效的治疗。⁹⁹Tc^m-MIBI(⁹⁹Tc^m-甲氧基异丁基异腈)是mdr1基因编码的P-gp(P-糖蛋白)和MRP(多药耐药相关蛋白)的转运底物,肿瘤细胞内⁹⁹Tc^m-MIBI摄取减低表明其P-gp的高表达,并与MRP的表达相关。因此,⁹⁹Tc^m-MIBI显像可在治疗前预测对化疗的反应,并为选择更有效的化疗策略提供依据。